Single-agent bevacizumab or lomustine versus a combination of bevacizumab plus lomustine in patients with recurrent glioblastoma (BELOB trial): a randomised controlled phase 2 trial

Walter Taal, Hendrika M. Oosterkamp, Annemiek M. E. Walenkamp, Hendrikus J. Dubbink, Laurens V. Beerepoot, Monique C. J. Hanse, Jan Buter, Aafke H. Honkoop, Dolf Boerman, Filip Y. F. de Vos, Winand N. M. Dinjens, Roelien H. Enting, Martin J. B. Taphoorn, Franchette W. P. J. van den Berkmortel, Rob L. H. Jansen, Dieta Brandsma, Jacoline E. C. Bromberg, Irene van Heuvel, Rene M. Vernhout, Bronno van der HoltMartin J. van den Bent*

*Corresponding author for this work

Research output: Contribution to journalArticleAcademicpeer-review

Original languageEnglish
Pages (from-to)943-953
JournalLancet oncology
Volume15
Issue number9
DOIs
Publication statusPublished - Aug 2014

Cite this